Castle Biosciences Announces Receipt of New York Laboratory Permit

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that it has received its Clinical Laboratory Permit from the New York State Department of Health, including approval for three clinical tests. The receipt of the New York permit allows patients in that state to benefit from the Company’s DecisionDx®-Melanoma, DecisionDx®-UM and DecisionDx®-PRAME molecular diagnostic tests that provide actionable molecular information to inform patient care decisions.

Continue reading

Applications are open for the National Medal of Technology and Innovation

The National Medal of Technology and Innovation (NMTI) is now accepting nominations for 2018. Awarded by the President of the United States, the NMTI is the nation’s highest honor for technological achievement. If you know of an individual, team, or company that has made an outstanding technological contribution to United States’ economic, environmental, or social well-being, you can submit nominations until the April 6 deadline. The nomination form, a sample recommendation letter, and FAQs are available on the NMTI website.Continue reading

RightBio Metrics Wins A First Place Patient Safety Innovation Award for the RightSpot®

RightBio Metrics was recently honored with a first place Patient Safety Innovation Award. Award recipients were announced on February 23rd in London, England during the 6th Annual World Patient Safety, Science & Technology Summit. The Patient Safety Movement Foundation ( received 55 submissions from 6 countries and awarded RightBio Metrics first place based on the RightSpot’s ability to help improve patient safety.

Continue reading